In the last decade, Immunotherapy has become a viable treatment option for many cancer patients. Unlike radiation and chemotherapy, Immunotherapy does not target cancer itself. Instead, it enables a patient’s own immune system to attack the disease. In most cases, immune-based treatments stimulate T cells, a specialised type of immune cell, to fight cancer. Further, Immunotherapy drugs called immune checkpoint inhibitors accomplish this by blocking checkpoint proteins that live on the surface of T cells and act as “brakes” to prevent the T cells from accidentally attacking healthy cells. Now a standard treatment for a growing list of cancers, checkpoint inhibitors have proven effective for treating several types of cancers, including melanoma, small cell lung cancer, non-small cell lung cancer, lymphoma and more. To summarise, Immunotherapy for cancer treatment magnifies the body’s natural immune response to cancer, with a side effect profile different from regular chemotherapy.
The science is evolving in terms of helping us identify which patients will benefit from Immunotherapy with the advantage that those who respond to Immunotherapy are likely to have sustained and durable responses. Consequently, such innovations pave the way for the decentralised manufacturing of novel cell therapies. Right now, amid a wide variety of vendors entering the industry with a set of advanced and integrated immunotherapy solutions, we are helping companies navigate through the best-of-breed organisations. The enlisted companies are transforming immunotherapy processes and treatments at the intersection of various disruptive technologies. Besides, the magazine also comprises insights from thought leaders in the sector on the industry trends, best practices, recent innovations, and their advice for aspiring CIOs.
We present to you Pharma Tech Outlook’s “Top 10 Immunotherapy Solution Providers in Europe – 2021.”
